PD 173074: Selective FGFR1/VEGFR2 Inhibition for Cancer Research

Executive Summary: PD 173074 is a small molecule FGFR tyrosine kinase inhibitor with high selectivity and nanomolar potency toward FGFR1 (IC₅₀ ≈ 21.5 nM) and moderate inhibition of VEGFR2 autophosphorylation (100–200 nM) (product information). It achieves its effect by ATP-competitive binding, enabling specific blockade of FGF- and VEGF-driven signaling relevant to angiogenesis and tumor proliferation (Yan et al. 2022). PD 173074 demonstrates over 1,000-fold selectivity over kinases such as PDGFR and c-Src, reducing off-target effects. The compound is widely used in in vitro and in vivo models, including mouse neovascularization and xenograft assays. APExBIO supplies PD 173074 as a solid with validated solubility in DMSO and ethanol, supporting reproducible research protocols.

Biological Rationale

Fibroblast growth factor receptor (FGFR) and vascular endothelial growth factor receptor 2 (VEGFR2) are essential mediators of angiogenesis and tumor cell proliferation. Dysregulated FGFR signaling is implicated in oncogenesis, metastasis, and therapy resistance in multiple solid tumors, including pancreatic adenocarcinoma and lung adenocarcinoma (Yan et al. 2022). Selective inhibition of these pathways is a validated approach for dissecting mechanisms of tumor progression and evaluating potential targeted therapies. PD 173074, as a benchmark selective FGFR1 inhibitor, enables precise functional interrogation of these signaling axes (see related review).

Mechanism of Action of PD 173074

PD 173074 is an ATP-competitive inhibitor that binds to the ATP-binding pocket of FGFR1, effectively blocking receptor autophosphorylation and downstream signaling. It also inhibits VEGFR2 autophosphorylation at higher concentrations. The compound displays an IC₅₀ of approximately 21.5 nM for FGFR1 kinase activity, and inhibits VEGFR2-mediated signaling in the 100–200 nM range. Importantly, its selectivity profile shows 1,000-fold lower activity against kinases such as PDGFR, c-Src, EGFR, and the insulin receptor, minimizing confounding effects in pathway dissection (product details). PD 173074's blockade of FGF-2-mediated effects results in inhibition of angiogenesis, tumor cell proliferation, and metastasis, which are central to its research utility (structural insights).

Evidence & Benchmarks

• PD 173074 inhibits FGFR1 kinase activity with an IC₅₀ of 21.5 nM under standard in vitro assay conditions (APExBIO).
• VEGFR2 autophosphorylation is inhibited in the 100–200 nM range, with >1,000-fold selectivity over PDGFR and other kinases (APExBIO).
• In mouse models, PD 173074 blocks corneal neovascularization and reduces tumor growth in colorectal cancer xenografts (Yan et al. 2022).
• PD 173074 has been used to identify FGFR inhibitors as potential therapies for pancreatic adenocarcinoma, based on transcriptomic drug sensitivity modeling (Yan et al. 2022).
• In head and neck squamous cell carcinoma and schizophrenia models, PD 173074 facilitates mechanistic exploration of FGFR signaling dependency (review).
• At higher concentrations (μM), PD 173074 reverses ABCB1/ABCC10-mediated multidrug resistance in tumor cells (product data).
• No significant toxicity is reported at effective dosing ranges in animal models (APExBIO).

This article extends prior summaries such as this focused review by providing updated benchmarks from recent translational modeling and clarifying solubility and workflow integration.

Applications, Limits & Misconceptions

PD 173074 is widely applied in cancer research for dissecting FGFR and VEGFR2 signaling. It is validated in in vitro cell culture, kinase assays, and in vivo models of angiogenesis and tumor progression. The compound's high selectivity supports studies targeting FGFR-driven oncogenic pathways and resistance mechanisms. Transcriptomic analyses in pancreatic adenocarcinoma highlight PD 173074 as a candidate for individualized drug sensitivity prediction (Yan et al. 2022). Its robust solubility in DMSO (≥26.18 mg/mL) and ethanol (≥108.4 mg/mL with ultrasound) enables flexible dosing strategies (APExBIO).

For advanced insight into the role of FGFR signaling in therapy resistance, see the contrast with CENPO super-enhancer research, which focuses on LUAD. This article clarifies how PD 173074 selects for FGFR/VEGFR2 pathways without confounding off-target effects.

Common Pitfalls or Misconceptions

• Not a pan-kinase inhibitor: PD 173074 does not broadly inhibit non-FGFR kinases; selectivity must be respected in experimental design.
• Solubility limitations: The compound is insoluble in water; DMSO or ethanol (with ultrasound) is required for solution preparation (APExBIO).
• Long-term solution storage: Solutions of PD 173074 are unstable; they should be freshly prepared and used promptly.
• Non-clinical status: PD 173074 is a research-use-only tool and not approved for therapeutic use in humans.
• Dose-dependent resistance reversal: Multidrug resistance reversal requires higher (μM) concentrations, which may not reflect routine kinase assay conditions.

Workflow Integration & Parameters

PD 173074 is supplied as a solid by APExBIO and should be stored at 4°C. The compound's high solubility in DMSO and ethanol supports diverse experimental workflows, from cell-based assays to animal studies. Below are protocol parameters derived from literature and product guidance:

Protocol Parameters

• Kinase inhibition assays: Use 10–50 nM for selective FGFR1 inhibition in cell-free systems.
• Cell culture studies: Apply 20–200 nM to block FGF-2-driven proliferation.
• Multidrug resistance reversal: Employ 1–10 μM to modulate ABCB1/ABCC10 activity in resistant tumor lines.
• Animal studies (i.p.): Dose at 1–2 mg/kg/day for anti-angiogenesis or tumor growth inhibition.
• Animal studies (oral): Typical range is 3–30 mg/kg, depending on model and target pathway.
• Solution preparation: Dissolve in DMSO (≥26.18 mg/mL) or ethanol (≥108.4 mg/mL, ultrasonic assistance); do not store solutions long-term.

For optimized study designs targeting FGFR/VEGFR2 pathways, review this workflow summary, which this article updates by including recent transcriptomic sensitivity evidence.

Conclusion & Outlook

PD 173074, as provided by APExBIO, is a gold-standard tool compound for selective inhibition of FGFR1 and VEGFR2 in cancer and angiogenesis research. Its high potency, robust selectivity, and validated performance in preclinical models make it indispensable for dissecting FGF/VEGF signaling. Recent transcriptomic analyses highlight its ongoing relevance for drug sensitivity prediction in pancreatic adenocarcinoma, while its solubility and workflow flexibility enable broad adoption. Future research will continue refining personalized strategies for FGFR pathway blockade, leveraging tools such as PD 173074 in mechanistic and translational studies (Yan et al. 2022).